In mice carrying mutations in GABRA1 or GABRG2, which model generalized epilepsies associated with impaired GABAA receptor function, vigabatrin markedly reduces seizure frequency and improves survival, likely by compensating for reduced synaptic inhibition through sustained increases in extracellular GABA [121,122]. Here, GABRA1 is linked to idiopathic generalized epilepsy.